Gary Buchschacher
Hematology & Oncology · Los Angeles, CANPI 1730250705
Payments from drug & device makers
Across 576 payments — averaging $13,726 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$4.1M
- AstraZeneca$2.3M
- GSK$476K
- Merck$398K
- Seagen Inc.$293K
- Pfizer$207K
- plus $170K from 7 others
Across 20 payments — averaging $203.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Speaking & faculty fees$1,84226%
- Travel & lodging$4,36762%
- Food & beverage$85912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 164 | $4,088,533 |
| AstraZeneca | 34 | $2,274,172 |
| GSK | 168 | $475,660 |
| Merck | 132 | $397,932 |
| Seagen Inc. | 16 | $292,895 |
| Pfizer | 14 | $206,791 |
| Mirati Therapeutics, Inc. | 5 | $105,124 |
| Astellas Pharma Global Development | 20 | $46,071 |
| E.r. Squibb & Sons, L.L.C. | 1 | $8,000 |
| Roche Products Limited | 8 | $4,147 |
| Eli Lilly | 3 | $4,005 |
| F. Hoffmann-la Roche AG | 3 | $1,842 |
| Astrazeneca UK Limited | 8 | $1,079 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$4,082
- Avastin$2,838
- Non-Covered Product$1,842
How this compares
$7,906,252 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 34 | $525,734 |
| XtandiEnzalutamide | 15 | $183,432 |
| Abiraterone Acetate | 44 | $7,130 |
| Imatinib Mesylate | 11 | $1,575 |
| Anastrozole | 50 | $1,395 |
| Tamoxifen Citrate | 15 | $500 |
| Alendronate Sodium | 25 | $245 |
| Prednisone | 23 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance | $206,791 | $525,73434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Los Angeles
- David BerzLos Angeles$43.3M
- Nicholas McAndrewLos Angeles$22.9M
- Antoni RibasLos Angeles$13M
- Gary SchillerLos Angeles$11.9M
- Matthew RettigLos Angeles$8.2M
- Lasika SeneviratneLos Angeles$8.1M
- Edward GaronLos Angeles$7.9M
- Gottfried KonecnyLos Angeles$7.6M
- Sven de VosLos Angeles$6.7M
- Jorge NievaLos Angeles$6.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.